Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 13 of 16
Mar 12, 2026The biotech startup Vima Therapeutics is advancing its drug development pipeline to target Parkinson’s disease, alongside other neurological movement disorders. With a significant funding increase, the company aims to address the underlying biology shared among diverse movement disorders.
Mar 9, 2026The emerging obesity drug Petrelintide has met the primary endpoints of a Phase 2 clinical trial, demonstrating safety and efficacy consistent with expectations. However, analysts note that the average weight loss achieved was below the more optimistic forecasts, triggering debates on its potential market position among increasingly crowded weight management therapies.
Mar 5, 2026The involvement of controversial figures in scientific research has always attracted scrutiny. The recent disclosure about Jeffrey Epstein's alleged participation in a genetics project at Harvard places spotlight on research protocols, consent validity, and institutional oversight. This post examines the implications and surrounding facts of this emerging mystery.
Mar 1, 2026Emerging from the legacy of Avidity Biosciences and supported by a substantial investment, Atrium Therapeutics is a new biotech company dedicated to developing RNA therapies for rare cardiac conditions. Their pipeline shines a light on a critical area with unmet medical needs, aiming to transform treatment options where none currently exist.
Feb 25, 2026The collaboration between Novo Nordisk and Vivtex marks a promising development in the pursuit of innovative oral therapies for complex metabolic disorders such as obesity and diabetes. This initiative is poised to expand treatment options beyond the existing injectable drugs, potentially enhancing patient adherence and therapeutic outcomes.
Feb 24, 2026The funding round marks a significant milestone for Slate Medicines as it prepares its Phase 1-ready antibody drug designed to block PACAP, aiming to address the substantial unmet need in migraine therapy. The asset was licensed from DartsBio Pharmaceuticals, reflecting international collaboration in biotech innovation.
Feb 22, 2026The preclinical Alzheimer’s drug relies on Korsana’s proprietary platform technology that enables antibodies to traverse the blood-brain barrier. This advancement parallels approaches by Roche and AbbVie, reflecting a significant leap in the therapeutic landscape against Alzheimer's disease.
Feb 19, 2026Current GLP-1 based obesity therapies, while effective for weight loss, present challenges including muscle loss and adherence issues. Innovators in the biotech field are exploring novel solutions such as preserving muscle mass, developing oral administration methods, and combining therapies to improve patient outcomes and sustain treatment adherence.
Feb 18, 2026Alzheimer’s disease remains one of the most challenging neurodegenerative conditions with urgent demand for effective treatments. Korsana’s innovative approach utilizes next-generation shuttling technology to bolster brain delivery of antibodies, potentially minimizing amyloid-related imaging abnormalities and improving therapeutic outcomes. This post delves into Korsana’s strategy, funding landscape, and implications for Alzheimer's treatment development.
Feb 18, 2026In a major advancement for treating wet age-related macular degeneration (AMD), Ocular Therapeutix reported that their novel drug Axpaxli met the primary endpoint in Phase 3 trials, demonstrating superior vision maintenance compared to Regeneron's established therapy Eylea. This success paves the way for regulatory filing and could shift treatment paradigms for wet AMD patients worldwide.
Feb 17, 2026Recent clinical results from Compass Pathways suggest that psilocybin-based medicines might soon gain regulatory approval for treating severe depression. These pioneering trials mark a hopeful step towards integrating psychedelic compounds into mainstream mental health care.
Feb 16, 2026Despite longstanding dominance in biotech innovation, the United States faces risks that could alter its pioneering status. This analysis explores the factors influencing this pivotal period in American innovation and the potential implications for the biotech sector.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.